chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 72.0
Sex: M
Vaccine: COVID19-2
Symptoms: Polycythaemia vera
Clinical narrative: Patient was just diagnosed with polycythemia vera, which was a blood cancer; This spontaneous case was reported by a patient family member or friend and describes the occurrence of POLYCYTHAEMIA VERA (Patient was just diagnosed with polycythemia vera, which was a blood cancer) in a 72-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 050D22A) for COVID-19 prophylaxis.     The patient's past medical history included COVID-19 in November 2020.    On 19-Oct-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced POLYCYTHAEMIA VERA (Patient was just diagnosed with polycythemia vera, which was a blood cancer) (seriousness criterion medically significant). At the time of the report, POLYCYTHAEMIA VERA (Patient was just diagnosed with polycythemia vera, which was a blood cancer) had not resolved.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  The patient was trying to find out if there was a correlation, or if anybody reported, between that hematologic problem and the Moderna vaccine. The reporter explained that her husband did not have a genetic marker. Reporter found that polycythemia can occured in 60 and older. Patient had his first two treatments where they take a pint of blood once a month to get the hematocrit to come down. Company comment This spontaneous case concerns a 72-year-old male patient with no medical history reported, who experienced the serious, medically significant, unexpected event of Polycythemia Vera. The patient received the fifth dose of mRNA-1273.222 (BA.4/BA.5). The event onset date was not provided, thus, exact latency between vaccination and onset of the event could not be assessed. It was reported that he was just diagnosed with Polycythemia Vera and received treatment with blood withdrawals which decreased his hematocrit. It was reported that he did not have a genetic marker. No further clinical information was provided for medical review. The patient's age could be a contributory risk factor for the event. The benefit-risk relationship of mRNA-1273.222 (BA.4/BA.5) is not affected by this report.   This case was linked to MOD-2023-729263 (Patient Link).
Sex: M
Vaccine: COVID19-2
Symptoms: Condition aggravated, Illness, Ophthalmic migraine, Stress, Vision blurred
Clinical narrative: Ocular migraine; stress seems to make it worse; chronic illness; vision will just get blurry/Sometimes there are patterns that move, usually just a blurriness; it's like looking through wax paper; Stress; This spontaneous case was reported by a patient family member or friend and describes the occurrence of OPHTHALMIC MIGRAINE (Ocular migraine), CONDITION AGGRAVATED (stress seems to make it worse), ILLNESS (chronic illness), VISION BLURRED (vision will just get blurry/Sometimes there are patterns that move, usually just a blurriness) and VISUAL IMPAIRMENT (it's like looking through wax paper) in an adult male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Chronic fatigue syndrome. Concomitant products included GLUTATHIONE and INSULIN GLARGINE (LANTUS SOLOSTAR) for an unknown indication.    In 2022, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced OPHTHALMIC MIGRAINE (Ocular migraine), CONDITION AGGRAVATED (stress seems to make it worse), ILLNESS (chronic illness), VISION BLURRED (vision will just get blurry/Sometimes there are patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper) and STRESS (Stress). At the time of the report, OPHTHALMIC MIGRAINE (Ocular migraine), CONDITION AGGRAVATED (stress seems to make it worse), ILLNESS (chronic illness), VISION BLURRED (vision will just get blurry/Sometimes there are patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper) and STRESS (Stress) had not resolved.            Concomitant product also included unspecified 150 mg thyroid medication.  It was reported that Patient received 3 doses of the Moderna COVID19 vaccine last year sometime.   The symptoms were ongoing now it was more frequent.  Treatment was none because nobody knows what to do they did not know what to ask for.   This case was linked to US-MODERNATX, INC.-MOD-2023-729354 (Linked Report). This case was linked to MOD-2023-729354 (Patient Link).
Sex: M
Vaccine: COVID19-2
Symptoms: Visual impairment
Clinical narrative: Ocular migraine; stress seems to make it worse; chronic illness; vision will just get blurry/Sometimes there are patterns that move, usually just a blurriness; it's like looking through wax paper; Stress; This spontaneous case was reported by a patient family member or friend and describes the occurrence of OPHTHALMIC MIGRAINE (Ocular migraine), CONDITION AGGRAVATED (stress seems to make it worse), ILLNESS (chronic illness), VISION BLURRED (vision will just get blurry/Sometimes there are patterns that move, usually just a blurriness) and VISUAL IMPAIRMENT (it's like looking through wax paper) in an adult male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Chronic fatigue syndrome. Concomitant products included GLUTATHIONE and INSULIN GLARGINE (LANTUS SOLOSTAR) for an unknown indication.    In 2022, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced OPHTHALMIC MIGRAINE (Ocular migraine), CONDITION AGGRAVATED (stress seems to make it worse), ILLNESS (chronic illness), VISION BLURRED (vision will just get blurry/Sometimes there are patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper) and STRESS (Stress). At the time of the report, OPHTHALMIC MIGRAINE (Ocular migraine), CONDITION AGGRAVATED (stress seems to make it worse), ILLNESS (chronic illness), VISION BLURRED (vision will just get blurry/Sometimes there are patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper) and STRESS (Stress) had not resolved.            Concomitant product also included unspecified 150 mg thyroid medication.  It was reported that Patient received 3 doses of the Moderna COVID19 vaccine last year sometime.   The symptoms were ongoing now it was more frequent.  Treatment was none because nobody knows what to do they did not know what to ask for.   This case was linked to US-MODERNATX, INC.-MOD-2023-729354 (Linked Report). This case was linked to MOD-2023-729354 (Patient Link).
Age: 71.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: vials were thawed directly from the freezer each time they needed to administer a dose; No adverse event; HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date), PRODUCT STORAGE ERROR (vials were thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event) in a 71-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     Patient had no known condition.     On 09-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 09-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vials were thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date), PRODUCT STORAGE ERROR (vials were thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date) and PRODUCT STORAGE ERROR (vials were thawed directly from the freezer each time they needed to administer a dose).    It was unknown if the patient received any othe vaccines in the 4 weeks prior to Covid-19 vaccine.  Concomitant product use was not provided by the reporter.  Vial size was reported as 2.5 ml. Vial did not undergo any temperature excursions.  Treatment information was not provided.  This case contains information about patient 9th out of 9 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-729345 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729345:Master case (patient 1)
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: no adverse event; 5 patients received the vaccine on 12-Jun-2023; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (5 patients received the vaccine on 12-Jun-2023) and NO ADVERSE EVENT (no adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 041H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-Jun-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (5 patients received the vaccine on 12-Jun-2023). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (5 patients received the vaccine on 12-Jun-2023) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (5 patients received the vaccine on 12-Jun-2023).    Concomitant product use was not provided by the reporter.  Expiry date of the suspect vaccine was reported as 07-Jun-2023.  Treatment information was not provided.  This case contains information about patient 3rd out of 5 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-728837 (Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-728837:Master Case
Age: 12.0
Sex: F
Vaccine: COVID19
Symptoms: Pancreatitis acute
Clinical narrative: Recurrent Acute pancreatitis; This literature-non-study case was reported in a literature article and describes the occurrence of PANCREATITIS ACUTE (Recurrent Acute pancreatitis) in a 12-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.       No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PANCREATITIS ACUTE (Recurrent Acute pancreatitis) (seriousness criterion medically significant). At the time of the report, PANCREATITIS ACUTE (Recurrent Acute pancreatitis) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered PANCREATITIS ACUTE (Recurrent Acute pancreatitis) to be related.    Concomitant and treatment medications were not reported.  Author present a case of an adolescent female without any known anatomic or metabolic pre-disposition, developing recurrent acute pancreatitis that was seemingly related to acute viral infection and COVID-19 vaccination. Company comment: This is a literature-non-study case concerning a 12-year-old female patient, with no medical history reported or any known anatomic or metabolic pre-disposition, who experienced the serious (due to medically significant) and unexpected AESI of pancreatitis acute, after receiving an unspecified booster dose of mRNA-1273 vaccine. The onset date of the event and the vaccination date were not reported; hence, latency cannot be assessed properly. No further clinical information was provided for medical reviewing. The author assessed an apparently relationship with acute viral infection and COVID-19 vaccination. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Age: 0.92
Sex: F
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; 11-month-old patient received a first dose (0.25ml) Bivalent Moderna COVID-19 vaccine from a vial with a pink cap on 15JUN2023; This spontaneous case was reported by a nurse and describes the occurrence of WRONG PRODUCT ADMINISTERED (11-month-old patient received a first dose (0.25ml) Bivalent Moderna COVID-19 vaccine from a vial with a pink cap on 15JUN2023) and NO ADVERSE EVENT (No adverse event) in an 11-month-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 15-Jun-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On 15-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (11-month-old patient received a first dose (0.25ml) Bivalent Moderna COVID-19 vaccine from a vial with a pink cap on 15JUN2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). On 15-Jun-2023, NO ADVERSE EVENT (No adverse event) outcome was unknown. At the time of the report, WRONG PRODUCT ADMINISTERED (11-month-old patient received a first dose (0.25ml) Bivalent Moderna COVID-19 vaccine from a vial with a pink cap on 15JUN2023) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (11-month-old patient received a first dose (0.25ml) Bivalent Moderna COVID-19 vaccine from a vial with a pink cap on 15JUN2023).    No concomitant medication was reported.  No treatment information was reported.
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No AEs were reported for any patient; HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date) and NO ADVERSE EVENT (No AEs were reported for any patient) in a 72-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     Concurrent medical conditions included Diabetes.    On 24-May-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 24-May-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date). On an unknown date, the patient experienced NO ADVERSE EVENT (No AEs were reported for any patient). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date) and NO ADVERSE EVENT (No AEs were reported for any patient) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No AEs were reported for any patient) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date).    Patient had no known relevant medical history, allergy, concomitant diseases and risk factor. No concomitant information was reported. Suspect product dosage text was reported as unknown. The 2.5ml vial was thawed directly from the freezer each time they needed to administer a dose. The vial did not underwent temperature excursions. No treatment information was provided. This case is reported for patient 1 out of 9 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-729367, US-MODERNATX, INC.-MOD-2023-729360, US-MODERNATX, INC.-MOD-2023-729381, US-MODERNATX, INC.-MOD-2023-729363, US-MODERNATX, INC.-MOD-2023-729366, US-MODERNATX, INC.-MOD-2023-729365, US-MODERNATX, INC.-MOD-2023-729359 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729367:Patient 9th US-MODERNATX, INC.-MOD-2023-729381:Patient 8th US-MODERNATX, INC.-MOD-2023-729360:Patient 6th US-MODERNATX, INC.-MOD-2023-729366:Patient 3rd US-MODERNATX, INC.-MOD-2023-729363:Patient 2nd US-MODERNATX, INC.-MOD-2023-729365:Patient 5th US-MODERNATX, INC.-MOD-2023-729359:Patient 4th
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Dose administered after Manufacturer Date of Expiry; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after Manufacturer Date of Expiry) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 045H22A) for COVID-19 prophylaxis.     It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 15-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 15-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after Manufacturer Date of Expiry). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after Manufacturer Date of Expiry) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after Manufacturer Date of Expiry).    No concomitant information was reported. Suspect product dosage text was reported as unknown. The 2 doses from 1 vial (2.5ml) was initially stored in the refrigerator on 15-Jun-2023 and did not underwent any temperature excursions. No treatment information was provided.   Reporter did not allow further contact
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Condition aggravated, Illness, Inappropriate schedule of product administration, Ophthalmic migraine, Stress
Clinical narrative: ocular migraines; vision will just get blurry/patterns that move, usually just a blurriness; it's like looking through wax paper; stress; stress seems to make it worse; chronic illness; the second dose on May 28 2021 and the first dose on May 6 or 7 2021; This spontaneous case was reported by a patient family member or friend and describes the occurrence of OPHTHALMIC MIGRAINE (ocular migraines), VISION BLURRED (vision will just get blurry/patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper), STRESS (stress) and CONDITION AGGRAVATED (stress seems to make it worse) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Chronic fatigue syndrome. Concomitant products included GLUTATHIONE and INSULIN GLARGINE (LANTUS SOLOSTAR) for an unknown indication.   In May 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (the second dose on May 28 2021 and the first dose on May 6 or 7 2021). In June 2021, the patient experienced OPHTHALMIC MIGRAINE (ocular migraines), VISION BLURRED (vision will just get blurry/patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper), STRESS (stress), CONDITION AGGRAVATED (stress seems to make it worse) and ILLNESS (chronic illness). At the time of the report, OPHTHALMIC MIGRAINE (ocular migraines), VISION BLURRED (vision will just get blurry/patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper), STRESS (stress), CONDITION AGGRAVATED (stress seems to make it worse) and ILLNESS (chronic illness) had not resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (the second dose on May 28 2021 and the first dose on May 6 or 7 2021) outcome was unknown.            Concomitant product also included unspecified 150 mg thyroid medication. The first dose was given on 6 or 7 May- 2021.  It was reported that Patient received 3 doses of the Moderna COVID19 vaccine last year sometime. Patient started to experience the symptoms two weeks after the second dose around the 14- Jun-2021. The symptoms were ongoing now it was more frequent. No treatment was given to the patient.   This case was linked to MOD-2023-729356 (Patient Link).
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Vision blurred, Visual impairment
Clinical narrative: ocular migraines; vision will just get blurry/patterns that move, usually just a blurriness; it's like looking through wax paper; stress; stress seems to make it worse; chronic illness; the second dose on May 28 2021 and the first dose on May 6 or 7 2021; This spontaneous case was reported by a patient family member or friend and describes the occurrence of OPHTHALMIC MIGRAINE (ocular migraines), VISION BLURRED (vision will just get blurry/patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper), STRESS (stress) and CONDITION AGGRAVATED (stress seems to make it worse) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Chronic fatigue syndrome. Concomitant products included GLUTATHIONE and INSULIN GLARGINE (LANTUS SOLOSTAR) for an unknown indication.   In May 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (the second dose on May 28 2021 and the first dose on May 6 or 7 2021). In June 2021, the patient experienced OPHTHALMIC MIGRAINE (ocular migraines), VISION BLURRED (vision will just get blurry/patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper), STRESS (stress), CONDITION AGGRAVATED (stress seems to make it worse) and ILLNESS (chronic illness). At the time of the report, OPHTHALMIC MIGRAINE (ocular migraines), VISION BLURRED (vision will just get blurry/patterns that move, usually just a blurriness), VISUAL IMPAIRMENT (it's like looking through wax paper), STRESS (stress), CONDITION AGGRAVATED (stress seems to make it worse) and ILLNESS (chronic illness) had not resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (the second dose on May 28 2021 and the first dose on May 6 or 7 2021) outcome was unknown.            Concomitant product also included unspecified 150 mg thyroid medication. The first dose was given on 6 or 7 May- 2021.  It was reported that Patient received 3 doses of the Moderna COVID19 vaccine last year sometime. Patient started to experience the symptoms two weeks after the second dose around the 14- Jun-2021. The symptoms were ongoing now it was more frequent. No treatment was given to the patient.   This case was linked to MOD-2023-729356 (Patient Link).
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; HCP stated they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date) and NO ADVERSE EVENT (No adverse event) in a 74-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     Patient had no known relevant medical history, allergy,concomitant diseases and risk factor. It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 26-May-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 26-May-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date).    No concomitant information was reported. Suspect product dosage text was reported as unknown. The 2.5ml vial was thawed directly from the freezer each time they needed to administer a dose. The vial did not underwent temperature excursions. No treatment information was provided. This case is reported for patient 2 out of 9 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-729345 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729345:same reporter
Age: 72.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: vial was thawed directly from the freezer each time they needed to administer a dose; No adverse event; HCP stated they accidentally administered the dose of Moderna COVID-19 Vaccine Bivalent after the expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered the dose of Moderna COVID-19 Vaccine Bivalent after the expiration date), PRODUCT STORAGE ERROR (vial was thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event) in a 72-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     Concurrent medical conditions included Asthma.    On 26-May-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 26-May-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered the dose of Moderna COVID-19 Vaccine Bivalent after the expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vial was thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered the dose of Moderna COVID-19 Vaccine Bivalent after the expiration date), PRODUCT STORAGE ERROR (vial was thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered the dose of Moderna COVID-19 Vaccine Bivalent after the expiration date) and PRODUCT STORAGE ERROR (vial was thawed directly from the freezer each time they needed to administer a dose).    It was unknown if the patient received any other vaccines in the 4 weeks prior to Covid-19 vaccine. Concomitant product use was not provided by the reporter. The dosage text of the suspect product was reported as unknown.   Vial size was reported as 2.5 ml. Vial did not undergo any temperature excursions. Treatment information was not provided.  This case contains information about patient 3rd out of 9 patients.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729345:master case
Age: 66.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: vials were thawed directly from the freezer each time they needed to administer a dose; No adverse event; HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date), PRODUCT STORAGE ERROR (vials were thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event) in a 66-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     No known conditions for relevant medical history/conditions, allergy, concomitant diseases and risk factor.     On 01-Jun-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 2.5 milliliter. On 01-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vials were thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date), PRODUCT STORAGE ERROR (vials were thawed directly from the freezer each time they needed to administer a dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date) and PRODUCT STORAGE ERROR (vials were thawed directly from the freezer each time they needed to administer a dose).    It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. Concomitant medication not reported.   The vial did not undergo any temperature excursions.   Treatment medication not reported.
Age: 68.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date) and NO ADVERSE EVENT (No adverse event) in a 68-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     Patient had no known relevant medical history, allergy, concomitant diseases and risk factor. It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 08-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 08-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (they accidentally administered dose of Moderna COVID-19 Vaccine Bivalent after the expiration date).    No concomitant information was reported. Suspect product dosage text was reported as unknown. The 2.5ml vial was thawed directly from the freezer each time they needed to administer a dose. The vial did not underwent temperature excursions. No treatment information was provided.    This case was linked to US-MODERNATX, INC.-MOD-2023-729345 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729345:same reporter
Age: 76.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date) and NO ADVERSE EVENT (No adverse event) in a 76-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     Patient had no known relevant medical history, allergy,concomitant diseases and risk factor.     On 07-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 07-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date).    It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. No concomitant information was reported. Suspect product dosage text was reported as unknown. The 2.5ml vial was thawed directly from the freezer each time they needed to administer a dose. The vial did not underwent temperature excursions. No treatment information was provided. This case is reported for patient 6 out of 9 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-729345 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729345:Same reporter
Age: 73.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Dose administered after 30-day Use By Date; No adverse event; HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date), PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event) in a 73-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     Concurrent medical conditions included Heart disorder.    On 02-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 02-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date), PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date) and PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date).    It was unknown patient did receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. No concomitant medication was reported.  The vial did not undergo any temperature excursions. No treatment information was reported.  This case contains information for patient 5 out of 9.   This case was linked to US-MODERNATX, INC.-MOD-2023-729345 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729345:Patient 1
Age: 77.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date.) and NO ADVERSE EVENT (No adverse event) in a 77-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     Patient had no known relevant medical history, allergy,concomitant diseases and risk factor.     On 08-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 08-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (HCP stated they accidentally administered 9 doses of Moderna COVID-19 Vaccine Bivalent after the expiration date.).    It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. No concomitant information was reported. Suspect product dosage text was reported as unknown. The 2.5ml vial was thawed directly from the freezer each time they needed to administer a dose. The vial did not underwent temperature excursions. No treatment information was provided. This case is reported for patient 8 out of 9 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-729345 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729345:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Bursitis
Clinical narrative: Bursitis; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Lot number: GK1337) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization Series Completed, Unknown Manufacturer), for Covid-19 immunization. The following information was reported: BURSITIS (non-serious), outcome "unknown".  No follow-up attempts are possible. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Therapeutic response unexpected
Clinical narrative: He received one dose of monovalent afterward and it seems to have helped his long term symptoms; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 26-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "covid delta ", start date: Aug2020 (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: THERAPEUTIC RESPONSE UNEXPECTED (non-serious), outcome "unknown", described as "He received one dose of monovalent afterward and it seems to have helped his long term symptoms". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Reporter cousin who was 26 years old caught covid delta in Aug2020 and has been suffering since. He received one dose of monovalent afterward and it seems to have helped his long term symptoms.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.